NEW HAVEN, Conn., Nov. 5, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has completed enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial

CALGARY, Nov. 5, 2019 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE:WLLW; OTCQB:CANSF) is pleased to announce that it has been approved to commence trading on The OTCQB® Venture Market (the "OTCQB"), beginning today, November 5, 2019, under the symbol "CANSF". This U.S. listing will provide

FRANKFURT, Germany, Nov. 5, 2019 /PRNewswire/ -- LOG Pharma Packaging announced today that it will launch its innovative patent pending line of ActiveGuard® CONNECT™ smart packaging solutions at CPhI Worldwide 2019 in Frankfurt, Germany from 5-7 November.

VANCOUVER, Nov. 5, 2019 /PRNewswire/ - Choom™ (CSE: CHOO) (OTCQB: CHOOF), an established adult use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce that it has secured a Development Permit for a retail location in Kitsilano, one of Vancouver's

REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for the Senza® Omnia™ Spinal Cord Stimulation (SCS)

CEDAR KNOLLS, N.J., Nov. 5, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, the unique proprietary bioactive composition made from fertilized egg yolks clinically proven to help build lean muscle, announced the expansion of its animal hea

DUBLIN, Nov. 5, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its third quarter 2019 financial results including GAAP net revenues of $4.05 billion, a 3.6 percent increase from the prior year quarter.

CAMBRIDGE, Mass., Nov. 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, is hosting its first R&D Day in New York City today. 

HERTFORDSHIRE, England and PITTSBURGH, Nov. 5, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three and nine months ended

LEXINGTON, Mass., Nov. 5, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter ended September 30, 2019.